



14 October 2011

Dear Shareholder,

Annual General Meeting

Please find enclosed the notice of the 2011 Annual General Meeting of the ordinary shareholders of QRxPharma Limited (the Company) which will be held at 10.00 am on Wednesday 16 November 2011, at the offices of DibbsBarker, Lawyers, of Level 8, 123 Pitt Street, Sydney.

The formal part of the Annual General Meeting will cover the ordinary business transacted each year, including the consideration of the Company's financial statements and remuneration report and the re-election of directors. This year the Annual General Meeting will also cover the following ordinary resolutions:

- Ratification of prior issue of Placement Shares
- Issue of Options to Chief Executive Officer – Dr John Holaday

Further details concerning these matters are contained in the explanatory statement that forms part of this notice of meeting.

If you are unable to attend the meeting in person, I encourage you to return the enclosed proxy form. The proxy form should be returned in the envelope provided, or faxed to our Share Registry on (02) 9287 0309 so that it is received by 10.00 am (Sydney time) on Monday 14 November, being not less than 48 hours before the time for holding the meeting. Alternatively proxy forms may also be lodged online at Link Market Services' website www.linkmarketservices.com.au in accordance with the instructions given there. You will be taken to have signed the proxy form if you lodge it in accordance with the instructions provided on the website.

The QRxPharma Annual Report for the year ended 30 June 2011 is now available on our website at www.qrxpharma.com. Printed copies of the report are distributed only to those shareholders who have elected to receive it in printed form.

Shareholders will have an opportunity to ask questions during the meeting, and are invited to join the Board for light refreshments at its conclusion. I look forward to welcoming you at the meeting.

Yours sincerely,

A handwritten signature in black ink that reads 'C. J. Campbell'.

Chris J Campbell
Company Secretary and Chief Financial Officer



NOTICE OF THE 2011 ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT

QRxPharma Limited
ABN 16 102 254 151

Notice is given that the Annual General Meeting of shareholders of QRxPharma Limited (the “**Company**”) will be held at the offices of DibbsBarker, Lawyers, Level 8, 123 Pitt Street, SYDNEY at 10:00 am (Sydney time) on Wednesday, 16 November 2011.

ORDINARY BUSINESS

Financial Statements and Reports

Receipt of the Company’s Financial Reports and the accompanying Directors’ Report, Directors’ Declarations and Independent Auditor’s Report for the year ended 30 June 2011.

Resolutions

1. Adoption of the Remuneration Report

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

“That the Remuneration Report for the year ended 30 June 2011 be adopted.”

Note that the vote on this resolution is advisory only and does not bind the Directors or the Company.

Voting Exclusion Statement

The Company will disregard any votes cast on the above resolution by key management personnel or their closely related parties.

However, the Company need not disregard a vote if:

- it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form; or
- it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

2. Election of Director – Dr Peter Farrell

To consider and, if thought fit to pass the following resolution as an ordinary resolution:

“That Dr Peter Farrell, who retires as a director of the Company by rotation in accordance with clause 6.1(f) (i) (B) of the Company’s Constitution, and being eligible for re-election, be re-elected as a director of the Company.”

SPECIAL BUSINESS

Resolution

3. Ratification of prior issue of Placement Shares

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

“That, for the purpose of Listing Rule 7.4, and for all other purposes, shareholders ratify the allotment and issue of 17,241,379 Placement Shares on the terms and conditions set out in the Explanatory Statement.”

Voting Exclusion Statement

The Company will disregard any votes cast on the above resolution by:

- any person who participated in the issue; and
- any associate of those persons.

However, the Company need not disregard a vote if:

- it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form; or
- it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

4. Issue of Options to Chief Executive Officer – Dr John Holaday

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

“That, for the purpose of Listing Rule 10.14, and for all other purposes, approval is given for the grant under the QRxPharma Employee Share Option Plan, of 250,000 options to Dr John Holaday on the terms and conditions set out in the Explanatory Statement.”

Voting Exclusion Statement

The Company will disregard any votes cast on the above resolution by key management personnel or their closely related parties. Also, in accordance with the notice requirements of ASX Listing Rule 10.15.5, the Company will disregard any votes cast on the above resolution by:

- all Directors of the Company; and
- any associate of those persons.

However, the Company need not disregard a vote if:

- it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form; or
- it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

By Order of the Board

A handwritten signature in cursive script that reads "C. J. Campbell".

Chris J Campbell
Company Secretary
14 October 2011

Determination of Entitlement to Attend and Vote

The Company has determined that the holders of the Company's ordinary shares for the purpose of the Annual General meeting will be the registered holders of ordinary shares at 7.00 pm (Sydney time) on Monday, 14 November 2011.

This notice is also being sent to JPMorgan Chase Bank as depositary agent of the Company's American Depositary Receipts (**ADR**). Holders of the ADRs are invited to attend the annual general meeting but are not entitled to vote on any of the proposed resolutions. However, holders of ADRs may, subject to the terms of the depositary agreement between JPMorgan Chase Bank and the holders of the ADRs, instruct the JPMorgan Chase Bank to vote the ordinary shares underlying their ADRs on their behalf.

Proxies

Ordinary shareholders have the right to appoint a proxy, who need not be an ordinary shareholder of the Company. If an ordinary shareholder is entitled to two or more votes they may appoint two proxies and may specify the percentage of votes that each proxy is appointed to exercise. A proxy form has been included for ordinary shareholders with this notice of meeting. The proxy form must be received by Link Market Services Limited, located at Level 12, 680 George Street, Sydney, NSW 2000, or by facsimile to Links on (02) 9287 0309 by no later than 10.00 am Sydney time on Monday, 14 November 2011 being not less than 48 hours before the time for holding the meeting. Alternatively proxy forms may also be lodged online at Link Market Services' website www.linkmarketservices.com.au in accordance with the instructions given there. You will be taken to have signed the proxy form if you lodge it in accordance with the instructions provided on the website.

The proposed Chairman of the meeting intends to vote undirected proxies in favour of each of the four resolutions.

Power of Attorney

If an ordinary shareholder has appointed an attorney to attend and vote at the meeting, or if a proxy form is signed by an attorney, the power of attorney must likewise be received by Link Market Services Limited, located at Level 12, 680 George Street, Sydney, NSW 2000, or by facsimile to Link on (02) 9287 0309 by no later than 10.00 am Sydney time on Monday, 14 November 2011, being not less than 48 hours before the time for holding the meeting.

Corporate Representatives

A member who is a body corporate may appoint an individual as a representative to exercise the member's voting rights at the Annual General Meeting (AGM) pursuant to section 250D of the *Corporations Act 2001* (Cth). Representatives will be required to present documentary evidence of their appointment on the day of the meeting.

EXPLANATORY STATEMENT

This Explanatory Statement has been prepared to assist shareholders with their consideration of the resolutions detailed in the Notice of Annual General Meeting dated 14 October 2011. This Explanatory Statement should be read with, and forms part of, the accompanying Notice of Meeting.

1. FINANCIAL STATEMENTS AND REPORTS

As required by section 317 of the *Corporations Act 2001* (Cth), the Financial Report, Directors' Report, Directors' Declarations and the Independent Audit Report of the Company for the financial year ended 30 June 2011 will be laid before the Annual General Meeting. Shareholders will be provided with the opportunity to raise questions in relation to the reports; however there will be no formal resolution put to the meeting.

2. RESOLUTION 1 – ADOPTION OF THE REMUNERATION REPORT

Background

The *Corporations Act 2001* (Cth) requires that listed companies include a remuneration report in their Directors' Report. The remuneration report is set out on pages 13 to 22 of the Company's Annual Report. The Remuneration Report includes information in respect of the Company's remuneration policies in respect of Directors and group executives, including the relationship between remuneration policies and the Company's performance, prescribed details of Directors and group executives, details of securities included in the remuneration of Directors and group executives and details of persons employed under a contract.

The resolution to adopt the remuneration report has been put to the members in accordance with section 250R(2) of the *Corporations Act 2001* (Cth). Any outcome, with respect to this resolution, is advisory only and does not bind the Directors or the Company.

The Chair will allow a reasonable opportunity at the meeting for shareholders as a whole to ask questions about or make comments on the Remuneration Report.

The Directors will consider the outcome of this vote and any comments made by shareholders on the Remuneration Report at the meeting when reviewing the Company's remuneration policies.

Recent changes to the *Corporations Act 2001* (Cth) – “Two Strikes” Rule

The *Corporations Act 2001* (Cth) was amended as at 1 July 2011 to include new provisions relating to directors' appointment and remuneration matters and proxy voting. This Notice of Meeting does not propose to include details of all of these changes, and will only mention the changes relevant to this Notice of Meeting.

The changes give shareholders the opportunity to spill a company's board of directors if at two consecutive AGMs 25% or more of the eligible votes cast are against the remuneration report.

The changes provide that:

- If 25% or more of the eligible votes cast at an AGM are against the remuneration report, the subsequent remuneration report must outline the board's proposed action in response (or state the reasons for any inaction).

- If 25% or more of the eligible votes cast at the next AGM are against the subsequent remuneration report, the shareholders must then vote at the end of that AGM on a resolution (known as the spill resolution) that a general meeting be convened at which all of the Company’s directors (other than the Managing Director) must submit themselves to a vote for re-election.
- If the spill resolution is carried by ordinary majority then a further general meeting (“Spill Meeting”) must be held within 90 days. All directors who were in office at the time of approval of the remuneration report considered at the second AGM (other than the managing director who is permitted to hold office indefinitely without being re-elected under the ASX Listing Rules) would cease to hold office immediately before the end of the Spill Meeting.
- Resolutions to appoint persons to offices that will be vacated immediately before the end of the Spill Meeting must be put to the vote at the meeting. If a director is re-appointed at the meeting the appointment continues as if uninterrupted.
- The Spill Meeting to consider the spill resolution need not be held if none of the directors being spilled remains in office at the end of the 90 day period.
- The changes to the *Corporations Act 2001* (Cth) include provisions to avoid a complete Board spill by ensuring that there are at least three directors following a Spill Meeting. These three positions will be occupied by:
 - the managing director; and
 - the two people who receive the highest proportion of votes in favour of their appointment at the Spill Meeting (even if less than 50% of the votes cast on their election are in favour of their re-appointment). If two or more individuals have the same proportion of votes, the managing director and any re-elected director have the power to choose which individual will be re-appointed, subject to confirmation at the following AGM.

Voting exclusion statement

For the purposes of the voting exclusion statement on Resolution 1:

“key management personnel” means those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any director (whether executive or otherwise) of the Company.

“closely related party” means: (a) a spouse or child of the member; (b) a child of the member’s spouse; (c) a dependent of the member or the member’s spouse; (d) anyone else who is one of the member’s family and may be expected to influence the member, or be influenced by the member, in the member’s dealing with the Company; (e) a company the member controls; or (f) a person otherwise prescribed by the regulations.

Where the Chair is appointed as a proxy, the Chair will vote all undirected proxies in favour of Resolution 1.

If you appoint the Chair as your proxy, and you check the box consenting to the Chair voting undirected proxies, then unless you include an express voting direction on your proxy form, you will be directing, and expressly consenting to the Chair to vote in favour of Resolution 1.

3. RESOLUTION 2 – RE-ELECTION OF DR PETER FARRELL AS DIRECTOR

Dr Peter Farrell has been an independent Non-Executive Director of the Company since 27 April 2007 and is Chairman of the Board. In accordance with the retirement by rotation requirements of the Company's Constitution and the ASX Listing Rules, Dr Peter Farrell retires and offers himself for re-election as a Director of the Company.

His experience, qualifications and special responsibilities are set out on pages 10 to 11 of the Company's Annual Report.

4. RESOLUTION 3 – RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES

Background

On 22 July 2011, the Company announced the issue of 17,241,379 Placement Shares at an issue price of \$1.45 per Share to raise \$24,999,999.55. The Placement Shares were issued on 27 July 2011.

The subscribers pursuant to this issue were not related parties of the Company.

Resolution 3 seeks shareholder ratification pursuant to ASX Listing Rule 7.4 for the issue of those Placement Shares (**Share Ratification**).

ASX Listing Rule 7.1 provides that a company must not, subject to specified exceptions, issue or agree to issue during any 12 month period any equity securities, or other securities with rights to conversion to equity (such as an option), if the number of those securities exceeds 15% of the number of securities in the same class on issue at the commencement of that 12 month period.

ASX Listing Rule 7.4 sets out an exception to ASX Listing Rule 7.1. It provides that where a company in general meeting ratifies the previous issue of securities made pursuant to ASX Listing Rule 7.1 (and provided that the previous issue does not breach ASX Listing Rule 7.1) those securities will be deemed to have been made with shareholder approval for the purpose of ASX Listing Rule 7.1.

By ratifying this issue, the Company will retain the flexibility to issue equity securities in the future up to the 15% annual placement capacity set out in ASX Listing Rule 7.1 without the requirement to obtain prior Shareholder approval.

Information required under Listing Rule 7.5

Pursuant to and in accordance with ASX Listing Rule 7.5, the following information is provided in relation to the Share Ratification:

- a) 17,241,379 Placement Shares were allotted;
- b) the issue price was \$1.45 per Share;
- c) the Shares issued were all fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares;
- d) the Shares were allotted and issued to professional and sophisticated investor clients of RBS Morgans Corporate Limited and Bell Potter Securities Limited; and
- e) the Company intends to use the funds raised from this issue to:
 - (i) progress MoxDuo[®]IR through FDA approval and commercialisation leading to product launch expected in 2012;

- (ii) progress the development of MoxDuo Controlled Release (CR); and
- (iii) provide additional working capital.

Each of the Directors recommends that shareholders vote in favour of Resolution 3.

5. RESOLUTION 4 – ISSUE OF OPTIONS TO DR JOHN HOLADAY

Background

The grant of options to Directors under the QRxPharma Employee Share Option Plan of the Company requires the approval of shareholders under Listing Rule 10.14.

Following Dr John Holaday's annual review of his performance for the year ended 30 June 2011, the Board has agreed, subject to receipt of the necessary shareholder approval, to grant 250,000 employee options, all on the same terms, to Dr John Holaday, the Chief Executive Officer of the Company.

The options are governed by the QRxPharma Employee Share Option Plan and are granted on terms consistent with options granted by the Company in previous years. The options will be granted for no cash consideration with an exercise price per option equal to the share price on the date of the grant of the options.

If approved the options will be granted immediately following approval by the shareholders at the Annual General Meeting and will expire seven years following the grant date of the options. The options vest over 3 years with the initial vesting on the first anniversary of the date of the grant and subsequent vestings in 8 equal tranches on the first day of each calendar quarter over the following 2 years. When exercisable, each option would entitle Dr John Holaday to subscribe for one fully paid ordinary share in the capital of the Company. Each ordinary share issued on exercise of an option will rank equally with all other ordinary shares then on issue.

Further information about the Company's remuneration framework for executive officers, including the use of employee options, is set out in the Remuneration Report contained in the Company's 2011 Annual Report. In summary terms, as a company building a specialty pharmaceutical business, the Board considers options a key tool in retaining and incentivising executive Directors while staying within the fiscal constraints of a growing company. Options act as a reward for past performance, as a long term incentive and as a retention mechanism.

Information required under Listing Rule 10.15

Under Listing Rule 10.14, the Company cannot grant the options without shareholder approval. Accordingly, shareholder approval is sought and the Company provides the following additional information in accordance with Listing Rule 10.15:

- a) The maximum number of options that will be issued to Dr John Holaday is 250,000.
- b) The maximum number of options that may be acquired by a Director for whom approval is required under ASX Listing Rule 10.14 is (when taken together with all other options issued under the QRxPharma Employee Share Option Plan) ten per cent of the diluted ordinary share capital of the Company as at the date of issue of the relevant options.
- c) The price or the formula for calculating the price of each share to be acquired under the QRxPharma Employee Share Option Plan is set out in the individual's share option agreement. In this case the exercise price will be equal to the share price on the date of the grant of the options. The acquisition price for an option granted to a Director is nil.

- d) There have been no securities issued pursuant to the QRxPharma Employee Share Option Plan to any Director since the last shareholder approval.
- e) Dr Peter Farrell, Dr Gary Pace, Michael Quinn, Dr John Holaday and Peter Campbell, each being Directors of the Company, are entitled to participate in the QRxPharma Employee Share Option Plan.
- f) No loan will be made by the Company to Dr John Holaday to assist him acquire the options.
- g) If approved, the Company will grant the options to Dr John Holaday immediately following approval by shareholders at the Annual General Meeting and not later than 30 November 2011.

Where the Chair is appointed as a proxy, the Chair will vote all undirected proxies in favour of Resolution 4.

If you appoint the Chair as your proxy, and you check the box consenting to the Chair voting undirected proxies, then unless you include an express voting direction on your proxy form, you will be directing, and expressly consenting to the Chair to vote in favour of Resolution 4.

Each of the Directors, other than Dr John Holaday, recommends that shareholders vote in favour of Resolution 4.



QRxPharma Limited

ABN 16 102 254 151

LODGE YOUR VOTE



ONLINE

www.linkmarketservices.com.au



By mail:
QRxPharma Limited
C/- Link Market Services Limited
Locked Bag A14
Sydney South NSW 1235 Australia



By fax: +61 2 9287 0309



All enquiries to: Telephone: (02) 8280 7111

SHAREHOLDER VOTING FORM

I/We being a member(s) of QRxPharma Limited and entitled to attend and vote hereby appoint:

STEP 1

APPOINT A PROXY

the Chairman of the Meeting (mark box)

OR if you are NOT appointing the Chairman of the Meeting as your proxy, please write the name of the person or body corporate (excluding the registered shareholder) you are appointing as your proxy

or failing the person/body corporate named, or if no person/body corporate is named, the Chairman of the Meeting, as my/our proxy and to vote for me/us on my/our behalf at the Annual General Meeting of the Company to be held at **10:00am on Wednesday, 16 November 2011, at the offices of Dibbs Barker Lawyers, Level 8, 123 Pitt Street Sydney** and at any adjournment or postponement of the meeting. The Chairman of the Meeting intends to vote all available proxies in favour of all resolutions.

Proxies will only be valid and accepted by the Company if they are signed and received no later than 48 hours before the meeting. Please read the voting instructions overleaf before marking any boxes with an

STEP 2

VOTING DIRECTIONS

Resolution 1

Adoption of the Remuneration Report

Resolution 3

Ratification of prior issue of Placement Shares

Resolution 2

Election of Director - Dr Peter Farrell

Resolution 4

Issue of Options to Chief Executive Officer - Dr John Holaday

i * If you mark the Abstain box for a particular Item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your votes will not be counted in computing the required majority on a poll.

Important for Resolutions 1 and 4 - If the Chairman of the Meeting is your proxy or is appointed as your proxy by default

By marking this box, you are directing the Chairman of the Meeting to vote in accordance with his voting intentions on all Resolutions as set out above and in the Notice of Meeting. If you do not mark this box, and you have not directed your proxy how to vote on those Resolutions the Chairman of the Meeting will not cast your votes on those Resolutions and your votes will not be counted in computing the required majority if a poll is called on these Resolutions. If you appoint the Chairman of the Meeting as your proxy you can direct him how to vote by either marking the boxes on any or all of the items in Step 2 above (for example if you wish to vote 'for', 'against' or 'abstain' from voting) or by marking this box (in which case the Chairman of the Meeting will vote in favour of all Resolutions).

The Chairman of the Meeting intends to vote all available proxies in favour of all Resolutions.

I/we direct the Chairman of the Meeting to vote in accordance with his voting intentions on all Resolutions (except where I/we have indicated a different voting intention above) and acknowledge that the Chairman of the Meeting may exercise my proxy even though Resolutions 1 and 4 are connected directly or indirectly with the remuneration of a member of the key management personnel and even if the Chairman of the Meeting has an interest in the outcome of that item and that votes cast by him, other than as proxy holder, would be disregarded because of that interest.

STEP 3

SIGNATURE OF SHAREHOLDERS - THIS MUST BE COMPLETED

Shareholder 1 (Individual)

Sole Director and Sole Company Secretary

Joint Shareholder 2 (Individual)

Director/Company Secretary (Delete one)

Joint Shareholder 3 (Individual)

Director

This form should be signed by the shareholder. If a joint holding, either shareholder may sign. If signed by the shareholder's attorney, the power of attorney must have been previously noted by the registry or a certified copy attached to this form. If executed by a company, the form must be executed in accordance with the company's constitution and the Corporations Act 2001 (Cth).

QRX PRX107



HOW TO COMPLETE THIS PROXY FORM

Your Name and Address

This is your name and address as it appears on the company's share register. If this information is incorrect, please make the correction on the form. Shareholders sponsored by a broker should advise their broker of any changes. **Please note: you cannot change ownership of your shares using this form.**

Appointment of a Proxy

If you wish to appoint the Chairman of the Meeting as your proxy, mark the box in Step 1. If the person you wish to appoint as your proxy is someone other than the Chairman of the Meeting please write the name of that person in Step 1. If you leave this section blank, or your named proxy does not attend the meeting, the Chairman of the Meeting will be your proxy. A proxy need not be a shareholder of the company. A proxy may be an individual or a body corporate.

Votes on Items of Business - Proxy Appointment

You may direct your proxy how to vote by placing a mark in one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

Appointment of a Second Proxy

You are entitled to appoint up to two persons as proxies to attend the meeting and vote on a poll. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by telephoning the company's share registry or you may copy this form and return them both together.

To appoint a second proxy you must:

- (a) on each of the first Proxy Form and the second Proxy Form state the percentage of your voting rights or number of shares applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded.
- (b) return both forms together.

Signing Instructions

You must sign this form as follows in the spaces provided:

Individual: where the holding is in one name, the holder must sign.

Joint Holding: where the holding is in more than one name, either shareholder may sign.

Power of Attorney: to sign under Power of Attorney, you must lodge the Power of Attorney with the registry. If you have not previously lodged this document for notation, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the *Corporations Act 2001*) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please indicate the office held by signing in the appropriate place.

Corporate Representatives

If a representative of the corporation is to attend the meeting the appropriate "Certificate of Appointment of Corporate Representative" should be produced prior to admission in accordance with the Notice of Meeting. A form of the certificate may be obtained from the company's share registry.

Lodgement of a Proxy Form

This Proxy Form (and any Power of Attorney under which it is signed) must be received at an address given below by **10:00am on Monday, 14 November 2011**, being not later than 48 hours before the commencement of the meeting. Any Proxy Form received after that time will not be valid for the scheduled meeting.

Proxy Forms may be lodged using the reply paid envelope or:



ONLINE  www.linkmarketservices.com.au

Login to the Link website using the holding details as shown on the proxy form. Select 'Voting' and follow the prompts to lodge your vote. To use the online lodgement facility, shareholders will need their "Holder Identifier" (Securityholder Reference Number (SRN) or Holder Identification Number (HIN) as shown on the front of the proxy form).



by mail:

QRxPharma Limited
C/- Link Market Services Limited
Locked Bag A14
Sydney South NSW 1235
Australia



by fax:

+61 2 9287 0309



by hand:

delivering it to Link Market Services Limited, Level 12, 680 George Street, Sydney NSW 2000.

**If you would like to attend and vote at the Annual General Meeting, please bring this form with you.
This will assist in registering your attendance.**